Aim: A is an irreversible ErbB family blocker that has shown promising clinical activity in pts
with SCC of the head/neck and lung. Here, we report results of LL8, a phase III trial that …

… to evaluate whether first-line erlotinib followed at progression by … treatment sequence in
patients with advanced NSCLC. … After progression, patients received second-line erlotinib 150 …

… 350 patients to receive erlotinib and 320 to receive placebo. We followed up patients until
March 31, 2011. 657 patients died; median overall survival did not differ between groups (…

… Total number of patients was 290. A group treated with chemotherapy … second line consisted
of 150 patients and a group treated with erlotinib in the second line consisted of 140 patients…

… tested here for second-line erlotinib initiation in patients with advanced-stage NSCLC are
within the limits considered acceptable for society, although patient selection based on clinical …

… afatinib has clinical efficacy as second-line treatment for patients with squamous cell carcinoma
of the lung. Afatinib reduced the risk of death compared with erlotinib and also improved …

… Patients were stratified by EGFR mutation type, ECOG PS, gender, and country. … , erlotinib
patients could crossover to receive GP and GP patients could crossover to receive erlotinib. All …

… We conducted a randomized, double-blind, multicenter, phase II trial to evaluate the
addition of sunitinib to erlotinib in patients with platinum-pretreated NSCLC. Data from 30 …

… The combination of pemetrexed with erlotinib as second-line treatment in patients with
advanced or metastatic non-squamous NSCLC yielded a statistically significant improvement in …

… , erlotinib was effective in patients with wild-… erlotinib arms (P = .02).23 In a recent phase
3 trial, a comparison of docetaxel with erlotinib as second-line or third-line treatment in patients …